𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Development of a novel high performance filtration system — Application for various hardly filterable materials

✍ Scribed by Hiroshi Satone; Takahisa Katsuoka; Kazuki Asai; Takahiro Yamada; Takamasa Mori; JunIchiro Tsubaki

Book ID
113860919
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
865 KB
Volume
213
Category
Article
ISSN
0032-5910

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of a novel high performance
Development of a novel high performance filtration system — Optimization of operating conditions
✍ Takahisa Katsuoka; Hiroshi Satone; Takahiro Yamada; Takamasa Mori; JunIchiro Tsu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 871 KB

A new filtration system with a spiral guide rod in a ceramic tube and slurry prepared in a well dispersed state has been developed. This paper discusses the optimization of operating conditions such as the effects of the spiral guide rod, the pitch of the spiral guide rod, the filtration pressure an

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti